| 1. |
Insulin resistance and Alzheimer's disease |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1371/1372,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 2. |
Are `farmaceuticals' the way of the future? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1371/1372,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 3. |
Many women discontinued use of combination HRT products following reports of health risks, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1371/1372,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 4. |
Paroxetine, venlafaxine improve QOL in OCD |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1371/1372,
2003,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 5. |
Early sumatriptan use improves outcomes, cuts costs in migraine |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1371/1372,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 6. |
SOLO: encouraging results for fosamprenavir |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1371/1372,
2003,
Page 7-8
D Jack,
Preview
|
|
摘要:
Fosamprenavir [GW433908], a water-soluble prodrug of the nonpeptide protease inhibitor amprenavir, is a new anti-HIV agent with the potential to be given once daily when combined with low-dose ritonavir. Results from a phase III study (SOLO) were presented at the Sixth International Congress on Drug Therapy in HIV Infection [Glasgow, Scotland; November 2002]. The majority of patients treated with the fosamprenavir/ritonavir combination achieved viral loads below the limits of detection, including high proportions of patients with high viral RNA levels, or low CD4+ cell counts, at baseline. Although nelfinavir had comparable efficacy in the overall patient population, the proportions of responders among nelfinavir recipients in these two subgroups was approximately 50% lower than among the patients treated with fosamprenavir/ritonavir. Furthermore, the proportion of patients experiencing virological failure at 48 weeks was higher in the nelfinavir, compared with the fosamprenavir/ritonavir, group.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 7. |
Bevacizumab plus fluorouracil and folinic acid beneficial in colorectal cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1371/1372,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 8. |
Pramlintide: beneficial adjuvant therapy for type 1 diabetes |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1371/1372,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 9. |
The Rho-kinase inhibitor fasudil prevents acetylcholine-induced myocardial ischaemia |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1371/1372,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 10. |
Rabeprazole: long-term efficacy in GERD |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1371/1372,
2003,
Page 11-12
C Bankhead,
Preview
|
|
摘要:
As a class, proton pump inhibitors (PPI) have demonstrated potent acid suppression capabilities with a favourable tolerability profile and have become the treatment of choice for acid-related disorders. The newest member of the PPI class, rabeprazole [`Aciphex'] showed durable efficacy in the treatment of erosive or ulcerative gastroesophageal reflux disease (GERD) in a pooled analysis of 5-year data from two multicentre studies, presented at the annual meeting of the American College of Gastroenterology [Seattle, US; October 2002]. This analysis showed that long-term treatment with rabeprazole was well tolerated and provided significant improvements in the symptoms of GERD. Relapse rates were reduced, and the time to relapse prolonged, in rabeprazole, compared with placebo, recipients.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
首页
